Advaxis ( ADXS) is a clinical development stage biotechnology company, developing safe and effective immunotherapies for cancer and infectious diseases with its lead construct, ADXS-HPV, being evaluated in five clinical trials for HPV-associated diseases. This stock closed up 3.7% to $3.87 in Tuesday's trading session.
Tuesday's Range: $3.72-$3.95
52-Week Range: $3.38-$3.95
Thursday's Volume: 516,000
Three-Month Average Volume: 199,533
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts